|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Alzheimer’s
Research and Development
Our scientists are investigating three key therapeutic
approaches that target the elimination and prevention of
production or aggregation of beta amyloid. In collaboration with
Wyeth, we are developing beta amyloid immunotherapies.
Separately, we have research programs focused on small molecule
inhibitors of beta secretase and gamma secretase, enzymes whose
actions result in the over-production of beta amyloid in the
brains of patients with Alzheimer’s disease. In addition,
in September 2006 we entered into a collaboration agreement with
Transition Therapeutics, Inc. (Transition) to develop AZD-103
(also referred to as AZD-103/ELND-005), a small molecule
therapeutic that acts by breaking down and preventing the
aggregation of beta amlyoid fibrils.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Alzheimer’s
Research and Development
Our scientists are investigating three key therapeutic
approaches that target the accumulation and production of beta
amyloid. In collaboration with Wyeth, we are developing amyloid
immunotherapies. Separately, we have research programs focused
on small molecule inhibitors of beta secretase and gamma
secretase, enzymes whose actions result in the over-production
of beta amyloid in the brains of patients with Alzheimer’s
disease.
| EXCERPTS ON THIS PAGE:
|
| |||||||
